Navigation Links
Sound Pharmaceuticals Receives Additional DoD Funding for Its Hearing Regeneration Product
Date:7/21/2008

SEATTLE, July 21 /PRNewswire/ -- Sound Pharmaceuticals (SPI) has received an R&D contract award from the ONR for approximately $1.6 million to optimize its lead drug candidate for hearing regeneration. SPI has developed a proprietary technology for regenerating auditory sensory cells within the inner ear of mammals involving p27Kip1, a cyclin dependent kinase inhibitor or CKI. CKIs shut down cell division or proliferation in many developing cells and tissues and are often expressed in adult organs to maintain cellular quiescence or terminal differentiation. In the hearing organ of mammals (cochlea), p27Kip1 prevents cellular proliferation and regeneration. For this reason, sensorineural hearing loss is irreversible and often progressive. Once auditory hair cells are lost they are never replaced. In p27 knockout mice, auditory hair cell regeneration occurs due to the unique ability of supporting cells to re-enter the cell cycle, proliferate and regenerate in to supporting cells and replacement hair cells. In p27 wild type mice, this proliferative and regenerative ability is absent. SPI has developed this novel technology into a drug that inhibits p27Kip1 in wild type cells and tissues, and is injecting that drug into the cochlea of deafened Guinea pigs. Results indicate that renewed supporting cell proliferation and hair cell regeneration occur in animals that have lost their hearing due to ototoxic or acoustic injury. In some animals, a return of auditory function has been observed. The ultimate goal of this work is to restore hearing to the severe to profoundly hearing impaired or deaf, especially those with recent traumatic injuries. This novel regenerating strategy may be applied to other non regenerating systems such as the brain or retina where p27Kip1 plays a similar role.

In 2005, the Office of Naval Research began funding this hearing regeneration project. This new funding brings the total level of funding on this specific p27 project to approximately $3 million.

Sound Pharmaceuticals, Inc. is a privately held biopharmaceutical company with a focus on developing the first drugs for hearing loss and brain injury. For more information please contact Jonathan Kil, MD, President and CEO, 206-634-2559 or visit http://www.soundpharma.com.


'/>"/>
SOURCE Sound Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Heel Ultrasound Helps Detect Fracture Risk
2. Accuracy of ultrasound screening in pregnancy: Effects of examiner and device quality unclear
3. Simple ultrasound exam may predict osteoporosis risk
4. UltraShape(R) Commences Pivotal Study for First Non-Invasive Fat Reduction and Body Contouring Device Using Non-Thermal Selective Focused Ultrasound
5. New Heart Ultrasound Research Shows Hope for Diagnosing and Treating Fatal Heart Conditions
6. Siemens New Ultrasound Platform Revolutionizes the Paradigm of Echocardiography
7. Mindrays DC-3 Color Ultrasound Gains U.S. FDA 510(k) Clearance
8. Can SonicMood Help to Significantly Lower High Blood Pressure? The Latest Research Answers With a Resounding YES!
9. World No Tobacco Day Sounds Urgent Call for Nations to Fight Tobacco Use, Save Lives
10. ALOKA to Unveil a New Compact ProSound Diagnostic Ultrasound System
11. Journal of Ultrasound In Medicine features bioeffects consensus report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the leading ... with Tennessee Counseling Association. This new relationship allows TherapySites to continue ... Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited about ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... ... a legally blind and certified personal trainer is helping to develop a weight loss fitness ... to fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... ANDOVER, Mass. and SAN CLEMENTE, Calif. ... California -based mobile pulmonary function testing company, is now ... portable PFT devices developed by ndd Medical Technologies , Inc. ... PFT testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ... CA , can get any needed testing done in the ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
Breaking Medicine Technology: